What's Happening?
ATCC and the Broad Institute have developed engineered isogenic cancer models to study resistance to targeted therapies, starting with osimertinib, an EGFR inhibitor used for non-small cell lung cancer (NSCLC). These models replicate resistance mechanisms,
allowing researchers to study multiple escape pathways more efficiently. The collaboration uses CRISPR gene editing and gene overexpression techniques to create drug-resistant NSCLC models. This approach provides a framework to understand therapeutic resistance and identify new vulnerabilities. The models will be integrated into the DepMap, a global effort to identify genetic vulnerabilities across cancer cell models, contributing to the development of a Response and Resistance Map (ResMap).
Why It's Important?
Understanding drug resistance is crucial for improving cancer treatment outcomes. The development of these engineered cancer models allows researchers to systematically study how tumors adapt to targeted therapies, potentially revealing new therapeutic strategies. By identifying resistance mechanisms, scientists can develop combination therapies to overcome resistance and improve patient survival rates. This research supports the broader goal of precision oncology, where treatments are tailored to individual genetic profiles, enhancing efficacy and reducing treatment failures. The collaboration between ATCC and the Broad Institute provides valuable resources for the global research community, advancing cancer research and treatment.
What's Next?
The engineered cancer models and associated data will be made accessible to the scientific community, facilitating further research into drug resistance and cancer vulnerabilities. The collaboration aims to extend this approach to additional cancer types, potentially leading to new breakthroughs in treatment strategies. As researchers continue to study these models, they may identify new therapeutic combinations that can improve outcomes for patients with resistant cancers. The integration of these models into the DepMap will help researchers worldwide explore new avenues in cancer treatment and precision oncology.
